CY1122143T1 - Φαρμακευτικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της b-raf, εναν αναστολεα του egfr και προαιρετικα εναν αναστολεα της ρι3κ-αλφα - Google Patents

Φαρμακευτικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της b-raf, εναν αναστολεα του egfr και προαιρετικα εναν αναστολεα της ρι3κ-αλφα

Info

Publication number
CY1122143T1
CY1122143T1 CY20191100461T CY191100461T CY1122143T1 CY 1122143 T1 CY1122143 T1 CY 1122143T1 CY 20191100461 T CY20191100461 T CY 20191100461T CY 191100461 T CY191100461 T CY 191100461T CY 1122143 T1 CY1122143 T1 CY 1122143T1
Authority
CY
Cyprus
Prior art keywords
inhibitor
optionally
pi3k
raf
egfr
Prior art date
Application number
CY20191100461T
Other languages
Greek (el)
English (en)
Inventor
Giordano Caponigro
Darrin Stuart
Laure Moutouh-De Parseval
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48980368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122143(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1122143T1 publication Critical patent/CY1122143T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CY20191100461T 2012-08-07 2019-04-30 Φαρμακευτικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της b-raf, εναν αναστολεα του egfr και προαιρετικα εναν αναστολεα της ρι3κ-αλφα CY1122143T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261680473P 2012-08-07 2012-08-07
PCT/US2013/053619 WO2014025688A1 (en) 2012-08-07 2013-08-05 Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor

Publications (1)

Publication Number Publication Date
CY1122143T1 true CY1122143T1 (el) 2020-11-25

Family

ID=48980368

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100461T CY1122143T1 (el) 2012-08-07 2019-04-30 Φαρμακευτικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της b-raf, εναν αναστολεα του egfr και προαιρετικα εναν αναστολεα της ρι3κ-αλφα

Country Status (39)

Country Link
US (1) US9474754B2 (2)
EP (2) EP3574904B1 (2)
JP (3) JP6342396B2 (2)
KR (1) KR102112885B1 (2)
CN (1) CN104519887B (2)
AR (1) AR092045A1 (2)
AU (1) AU2013299841B8 (2)
CA (1) CA2879548C (2)
CL (1) CL2015000294A1 (2)
CO (1) CO7200273A2 (2)
CY (1) CY1122143T1 (2)
DK (1) DK2882440T3 (2)
EA (1) EA028420B1 (2)
EC (1) ECSP15008695A (2)
ES (1) ES2717911T3 (2)
GT (1) GT201500025A (2)
HK (1) HK1211831A1 (2)
HR (1) HRP20190537T1 (2)
HU (1) HUE042877T2 (2)
IL (1) IL236934B (2)
IN (1) IN2015DN00450A (2)
JO (1) JOP20130236B1 (2)
LT (1) LT2882440T (2)
MA (1) MA37829A1 (2)
MX (1) MX359403B (2)
MY (1) MY176031A (2)
NZ (1) NZ703940A (2)
PE (2) PE20191655A1 (2)
PH (1) PH12015500246A1 (2)
PL (1) PL2882440T3 (2)
PT (1) PT2882440T (2)
RS (1) RS58734B1 (2)
SG (1) SG11201500321YA (2)
SI (1) SI2882440T1 (2)
TN (1) TN2015000027A1 (2)
TR (1) TR201904980T4 (2)
TW (1) TWI607754B (2)
UA (1) UA115786C2 (2)
WO (1) WO2014025688A1 (2)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201904980T4 (tr) * 2012-08-07 2019-05-21 Novartis Ag Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar.
UA118846C2 (uk) 2013-03-21 2019-03-25 Новартіс Аг Комбінована терапія
WO2015145388A2 (en) * 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
ES2686549T3 (es) * 2014-06-16 2018-10-18 Worldwide Innovative Network Método para seleccionar una triterapia personalizada para el tratamiento del cáncer
WO2016193955A1 (en) * 2015-06-04 2016-12-08 Giorgio Stassi Combinations of kinase inhibitors for treating colorectal cancer
CN107921037A (zh) * 2015-08-28 2018-04-17 诺华股份有限公司 含pi3k抑制剂alpelisib和b‑raf抑制剂达拉菲尼的药物组合；该组合在治疗或预防癌症中的应用
EP3380097A2 (en) * 2015-08-28 2018-10-03 Novartis AG Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancer
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
MX387795B (es) 2016-06-03 2025-03-19 Array Biopharma Inc Combinaciones farmaceuticas.
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
ES2952265T3 (es) 2017-05-02 2023-10-30 Novartis Ag Terapia combinada que comprende un inhibidor de Raf y trametinib
JP2020529411A (ja) * 2017-08-03 2020-10-08 ノバルティス アーゲー 第三世代ｅｇｆｒチロシンキナーゼ阻害剤とｒａｆ阻害剤の治療用組合せ
JP7640458B2 (ja) 2018-10-05 2025-03-05 アンナプルナ バイオ インコーポレイテッド Ａｐｊ受容体活性に関連する状態を処置するための化合物および組成物
TWI909513B (zh) * 2019-01-25 2025-12-21 英屬開曼群島商百濟神州有限公司 作為ｂ-ｒａｆ激酶二聚體抑制劑之化合物及其製備方法
WO2020164997A1 (en) * 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
ES3025633T3 (en) 2019-05-13 2025-06-09 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
JPWO2023145530A1 (2) * 2022-01-27 2023-08-03
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
KR20250069903A (ko) * 2022-09-26 2025-05-20 맵큐어, 엘엘씨 암 치료를 위한 B-Raf 저해제와 항-EGFR 항체의 조합물
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib
WO2025262686A1 (en) * 2024-06-20 2025-12-26 Ilan Paz Devices, systems and methods for optimized, personalized administration of oral dosage forms

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
JP2010523670A (ja) 2007-04-10 2010-07-15 エクセリクシス， インク． Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
IN2012DN01403A (2) * 2009-08-24 2015-06-05 Genentech Inc
JO3002B1 (ar) * 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
CN102665720A (zh) 2009-10-12 2012-09-12 葛兰素史密斯克莱有限责任公司 组合
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
CA2815492C (en) * 2010-11-08 2019-04-09 Novartis Ag Use of 2-carboxamide cycloamino urea derivatives in the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
CN104185631A (zh) 2011-11-10 2014-12-03 纪念斯隆-凯特琳癌症中心 用2-氨基-4H-萘并[1,2-b]吡喃-3-甲腈治疗卵巢癌
CN108542906A (zh) * 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
TR201904980T4 (tr) * 2012-08-07 2019-05-21 Novartis Ag Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar.

Also Published As

Publication number Publication date
JOP20130236B1 (ar) 2021-08-17
AU2013299841A8 (en) 2017-01-05
JP2015524472A (ja) 2015-08-24
NZ703940A (en) 2018-04-27
US9474754B2 (en) 2016-10-25
TW201410247A (zh) 2014-03-16
ECSP15008695A (es) 2019-03-29
JP2018109022A (ja) 2018-07-12
EA201590332A1 (ru) 2015-06-30
PE20191655A1 (es) 2019-11-07
CO7200273A2 (es) 2015-02-27
IL236934B (en) 2018-11-29
GT201500025A (es) 2017-09-28
PL2882440T3 (pl) 2019-07-31
EP3574904A1 (en) 2019-12-04
AR092045A1 (es) 2015-03-18
MA37829A1 (fr) 2017-01-31
IN2015DN00450A (2) 2015-06-26
HUE042877T2 (hu) 2019-07-29
DK2882440T3 (da) 2019-05-06
EA028420B1 (ru) 2017-11-30
MX359403B (es) 2018-09-26
PE20150673A1 (es) 2015-05-20
CN104519887B (zh) 2017-06-27
MY176031A (en) 2020-07-22
ES2717911T3 (es) 2019-06-26
PH12015500246B1 (en) 2015-03-30
AU2013299841A1 (en) 2015-02-12
RS58734B1 (sr) 2019-06-28
KR102112885B1 (ko) 2020-05-19
US20150265616A1 (en) 2015-09-24
SG11201500321YA (en) 2015-04-29
CN104519887A (zh) 2015-04-15
LT2882440T (lt) 2019-04-25
HRP20190537T1 (hr) 2019-06-28
HK1211831A1 (zh) 2016-06-03
CL2015000294A1 (es) 2015-05-08
EP3574904B1 (en) 2026-03-04
UA115786C2 (uk) 2017-12-26
PT2882440T (pt) 2019-04-23
KR20150040905A (ko) 2015-04-15
BR112015002384A8 (pt) 2019-07-30
TWI607754B (zh) 2017-12-11
CA2879548A1 (en) 2014-02-13
EP2882440B1 (en) 2019-02-27
EP2882440A1 (en) 2015-06-17
MX2015001732A (es) 2015-06-03
JP6595024B2 (ja) 2019-10-23
AU2013299841B2 (en) 2016-11-24
AU2013299841B8 (en) 2017-01-05
CA2879548C (en) 2020-07-21
BR112015002384A2 (pt) 2017-07-04
WO2014025688A1 (en) 2014-02-13
TR201904980T4 (tr) 2019-05-21
TN2015000027A1 (en) 2016-06-29
HK1204976A1 (en) 2015-12-11
JP6342396B2 (ja) 2018-06-13
JP2020019780A (ja) 2020-02-06
JP6974669B2 (ja) 2021-12-01
SI2882440T1 (sl) 2019-05-31
PH12015500246A1 (en) 2015-03-30

Similar Documents

Publication Publication Date Title
CY1122143T1 (el) Φαρμακευτικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της b-raf, εναν αναστολεα του egfr και προαιρετικα εναν αναστολεα της ρι3κ-αλφα
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
MX2016008362A (es) Combinaciones farmaceuticas.
CY1120506T1 (el) Θεραπευτικα δραστικες ενωσεις και μεθοδοι χρησης αυτων
IL254377B (en) Selective akr1c3 reductase activated prodrugs and their use for treating cancer patients
MX360045B (es) Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
EA201890006A1 (ru) Применение экзосом для лечения болезни
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
MX2017005875A (es) Metodos para tratar enfermedades oculares.
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
CY1122746T1 (el) Ιατρικες αγωγες με βαση την αναμορελινη
CY1126041T1 (el) Σκευασμα φαρμακου για χρηση στον αποτελεσματικο ελεγχο οξεος ή/και χρονιου πονου
MX382776B (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
CY1117438T1 (el) Μεθοδος για την προληψη και την θεραπευτικη αντιμετωπιση της σηψης
MX377510B (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
HK1252514A1 (zh) 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂
UA115250C2 (uk) Фармацевтичні комбінації
CL2016000170A1 (es) Combinación de oxicodona y naloxona para su uso en el tratamiento del dolor en pacientes que sufren de dolor y una enfermedad que resulta en disbiosis intestinal y/o aumento del riesgo de la translocación bacteriana intestinal.
EA201691964A1 (ru) Конъюгаты для доставки лекарственного средства для лечения устойчивой формы рака и для применения в комбинированной терапии
AR102494A1 (es) Métodos para tratar enfermedades oculares
CY1121354T1 (el) Μεθοδοι θεραπευτικης αντιμετωπισης ή προληψης του ασθματος μεσω χορηγησης ανταγωνιστη il-4r